1
Novel therapeutic targets are needed to design treatments to alleviate the cardiovascular burden of CKD.
2
Conclusions: Early intensive multifactorial treatment was not associated with a significant reduction in total cardiovascular burden at 5 years.
3
Taurine, as a dietary supplement, represents a potential new therapeutic agent to reduce the cardiovascular burden from iron-overload conditions.
4
Focusing on first events in cardiovascular disease prevention trials underestimates the total cardiovascular burden to patients and the health service.
5
Thus, disorders of calcium balance and homeostasis due to CKD-MBD may play a role in the high cardiovascular burden observed in patients with CKD.